20/20 Biolabs, Inc. 10-Q filing
Filed 2026-05-20 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001213900-26-059542
- Form type
- 10-Q
- CIK
- 0001139685
- Primary document
- https://www.sec.gov/Archives/edgar/data/1139685/000121390026059542/ea0291218-10q_2020bio.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for 20/20 Biolabs, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $353,375 | - | - |
| Cost Of Revenue | $290,491 | - | - |
| Gross Profit | $62,884 | - | - |
| Operating Income | $-1.4M | - | - |
| Net Income | $-2.2M | - | - |
| Eps Basic | -0.28 | - | - |
| Eps Diluted | -0.28 | - | - |
| Cash And Equivalents | $4.2M | - | - |
| Total Assets | $5.8M | - | - |
| Total Liabilities | $3.0M | - | - |
| Shareholders Equity | $2.6M | - | - |
| Operating Cash Flow | $-1.3M | - | - |